Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Researcher Spotlight: Wen-Hsuan Wendy Lin, MD, PhD COLUMBIA UNIVERSITY Peripheral T-cell lymphomas (PTCL) represent a group of aggressive blood cancers with poor outcomes. A common phenomenon in PTCL is the development of a proinflammatory microenvironment, in which lymphoma cells recruit…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD Anderson Cancer Center Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Schroder Family Scholar Post-transplant lymphoproliferative disorders (PTLD) are an aggressive group of lymphomas that occur in the setting of immunosuppression after solid organ transplant. There are very few…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Kanti R. Rai, MD Clinical Scholar Richter’s transformation (RT) represents a devastating progression of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) into an aggressive B-cell lymphoma. Prognosis with RT is…
Researcher Spotlight: Swetha Kambhampati, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Eric Cohen Distinguished Scholar Patients with diffuse large B cell lymphoma (DLBCL) who experience relapse after chimeric antigen receptor (CAR) T cell therapy have limited treatment options, and there…
Researcher Spotlight: Julie Erika Haydu, MD, PhD MASSACHUSETTS GENERAL HOSPITAL Runge Lymphoma Project Scholar Follicular lymphoma (FL) remains an incurable disease with current treatment options. Initial treatment of FL often involves the use of chemotherapy, and there are no approved…
Researcher Spotlight: Daniel Ermann, MD The University of Utah Patients with chronic lymphocytic leukemia (CLL) are at increased risk for infections due to the immune dysfunction associated with the disease. Bacterial pneumonia is a particular concern, and while vaccination with…